A Study of LY3437943 in Healthy Participants With a High Body Mass Index

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: LY3437943

• Registration Number: NCT05959096
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the body to get rid of it when given subcutaneously (SC, under the skin) in the upper arm and thigh compared to the abdomen in healthy participants with high body mass index (BMI) in Part A. In Part B, the participants receive LY3437943 intravenously (IV, through a vein) where the safety and tolerability of LY3437943 are evaluated and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 157 days and 99 days for Part A and Part B, respectively.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-07-17
• Study First Submitted QC: 2023-07-17
• Study Start: 2023-07-18
• Study First Posted: 2023-07-25
• Primary Completion: 2024-07-25
• Study Completion: 2024-07-25
• Status Verified: 2024-09
• Last Update Submitted: 2024-09-30
• Last Update Posted: 2024-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

• Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures
• Body mass index (BMI) between 27.0 and 45.0 kilograms per meter squared (kg/m²), inclusive
• Are agreeable to receiving study treatment by injections under the skin or through a vein.

Exclusion Criteria

• Have a history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form)
• Have a significant history of, or presence of, any of the following disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
• Have known allergies to LY3437943, related compounds, or any components of the formulation
• Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e cigarettes (nicotine and non nicotine) per day.
• Is a known user of drugs of abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LY3437943 (Part A)	LY3437943	LY3437943 administered subcutaneously (SC) in either thigh, upper arm, or abdomen
LY3437943 (Part B)	LY3437943	LY3437943 administered intravenously (IV)

Primary Outcome Measures

Name	Time	Method
Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943	Predose on Day 1 up to 43 days postdose (Part A)	Part A: PK: AUC(0-∞) of LY3437943
Part A: PK: Maximum Concentration (Cmax) of LY3437943	Predose on Day 1 up to 43 days postdose (Part A)	Part A: PK: Cmax of LY3437943

Secondary Outcome Measures

Name	Time	Method
Part B: PK: Maximum Concentration (Cmax) of LY3437943	Predose on Day 1 up to 71 days postdose (Part B)	Part B: PK: Cmax of LY3437943
Part B: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943	Predose on Day 1 up to 71 days postdose (Part B)	Part B: PK: AUC(0-∞) of LY3437943

Trial Locations

Locations (1)

Fortrea Clinical Research Unit; 🇺🇸 Daytona Beach, Florida, United States